The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze)., and Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | IMMUNOPLANT: linvoseltamab immuno-consolidation to drive MRD negativity in newly diagnosed myeloma
Dickran Kazandjian, MD, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, shares the encouraging results of the IMMUNOPLANT study (NCT06376526), a Phase II trial investigating the use of abbreviated fixed-duration linvoseltamab immuno-consolidation to deepen responses in patients with newly diagnosed multiple myeloma (MM) who are measurable residual disease (MRD) positive after initial combination therapy. Patients enrolled in the trial had been treated with standard triplet/quad-based combination therapy and attained a very good partial response (VGPR) or better, but remained MRD positive by clonoSEQ. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The idea of the IMMUNOPLANT study is really to use our new bispecific T-cell engaging therapies as immunotherapy and immunoconsolidation for newly diagnosed multiple myeloma. As you know, the paradigm treatment for multiple myeloma nowadays involves a quadruplet-based therapy upfront for most patients, and most patients do well, but still about a third to a half of patients don’t attain that very deep MRD-negative remission...
The idea of the IMMUNOPLANT study is really to use our new bispecific T-cell engaging therapies as immunotherapy and immunoconsolidation for newly diagnosed multiple myeloma. As you know, the paradigm treatment for multiple myeloma nowadays involves a quadruplet-based therapy upfront for most patients, and most patients do well, but still about a third to a half of patients don’t attain that very deep MRD-negative remission. So when we say MRD-negative, we mean 10 to the minus 6 sensitivity, so to be able to detect one bad cell out of a million. So a lot of times, those patients would definitely move on to get high-dose chemotherapy with melphalan usually and stem cell rescue. We call that an autologous transplant.
The idea of the IMMUNOPLANT was to see if we can use fixed four cycles of bispecific therapy called linvoseltamab to kind of drive those responses to MRD negativity. So originally the trial was designed for 25 patients. It met its initial first stage futility. And here at ASH, we presented as of November 1, 2025, our updated data where all 25 patients have been enrolled. 19 patients have received at least four cycles of treatment. And the overall summary of the responses is that of the 18 patients who were evaluable for MRD negativity, all 18 patients have attained MRD negativity. So the rate, obviously, is 100%, which is fairly profound, as you can imagine.
Of those patients, 10 of those patients have actually made it to the six-month bone marrow biopsy milestone to confirm that they’re still MRD negative, and all 10 remain MRD negative after six months. So just to remind people, the way the trial was designed was there was fixed four cycles of therapy. Some patients received a fifth and a sixth, but so far only two patients required the fifth and sixth cycle. But the point is, after the linvoseltamab immunoconsolidations, patients moved on to standard-of-care maintenance treatment, which in most cases was lenalidomide therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
